Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis

Background The impact of aging on the effectiveness of immune checkpoint inhibitors (ICIs) remains controversial, and little is known on the subject in adults aged ≥ 75 years. Objective The objective of this comprehensive meta-analysis was to assess the efficacy of ICIs in patients aged ≥ 75 years....

Full description

Saved in:
Bibliographic Details
Published in:Drugs & aging 2020-10, Vol.37 (10), p.747-754
Main Authors: Landre, Thierry, Des Guetz, Gaetan, Chouahnia, Kader, Fossey-Diaz, Virginie, Culine, Stéphane
Format: Article
Language:English
Subjects:
Age
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antigens
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis
B7-H1 Antigen - antagonists & inhibitors
Cancer therapies
Clinical trials
Confidence intervals
CTLA-4 Antigen - antagonists & inhibitors
Cytotoxicity
Female
Gastric cancer
Geriatrics/Gerontology
Humans
Immune Checkpoint Inhibitors - administration & dosage
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Internal Medicine
Kidney cancer
Ligands
Lung cancer
Male
Medicine
Medicine & Public Health
Melanoma
Meta-analysis
Monoclonal antibodies
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - mortality
Original Research Article
Pharmacology/Toxicology
Pharmacotherapy
Population
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Proportional Hazards Models
Randomized Controlled Trials as Topic
Survival Analysis
Systematic review
Targeted cancer therapy
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The impact of aging on the effectiveness of immune checkpoint inhibitors (ICIs) remains controversial, and little is known on the subject in adults aged ≥ 75 years. Objective The objective of this comprehensive meta-analysis was to assess the efficacy of ICIs in patients aged ≥ 75 years. Methods We performed a meta-analysis of published randomized controlled trials concerning ICIs (as monotherapy or in combination) versus standard therapy in patients with advanced solid tumors between January 2010 and January 2020. We compared overall survival between older (aged ≥ 75 years) and younger (
ISSN:1170-229X
1179-1969
DOI:10.1007/s40266-020-00788-5